Cover Image
市場調查報告書

週邊動脈疾病 (PAD):現在、未來市場參與企業

Peripheral Artery Disease - Current and Future Players

出版商 GlobalData 商品編碼 370552
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
週邊動脈疾病 (PAD):現在、未來市場參與企業 Peripheral Artery Disease - Current and Future Players
出版日期: 2015年10月01日 內容資訊: 英文 85 Pages
簡介

本報告提供全球週邊動脈疾病 (PAD)的治療藥市場上現有/新加入企業相關分析,整體市場的未來展望和促進、阻礙因素,現在調查、未來的競爭趨勢,主要企業簡介(企業概要,企業發展,財務狀況,SWOT分析)等。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 市場預測

  • 全球市場
    • 市場預測
    • 促進、阻礙因素:全球市場課題

第4章 現在、未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Bayer
    • Janssen (Johnson & Johnson)
    • AstraZeneca
    • Merck & Co.
    • Sanofi
    • Pfizer
    • Bristol-Myers Squibb
    • 大塚集團

第5章 附錄

圖表一覽

目錄
Product Code: GDHC1052FPR

GlobalData has released its pharma report, "Peripheral Artery Disease - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Peripheral Artery Disease Market. The report identifies and analyses the key companies shaping and driving the global Peripheral Artery Disease market. The report provides insight into the competitive Peripheral Artery Disease landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Peripheral Artery Disease
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Peripheral Artery Disease sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Peripheral Artery Disease market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Peripheral Artery Disease market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview and Trends in Corporate Strategy
  • 4.2. Company Profiles
    • 4.2.1. Bayer
    • 4.2.2. Janssen (Johnson & Johnson)
    • 4.2.3. AstraZeneca
    • 4.2.4. Merck & Co.
    • 4.2.5. Sanofi
    • 4.2.6. Pfizer
    • 4.2.7. Bristol-Myers Squibb
    • 4.2.8. Otsuka Holdings

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed PAD Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. Drugs Included in Each Therapeutic Class
    • 5.4.4. Launch and Patent Expiry Dates
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Individual Drug Assumptions
    • 5.4.7. Generic Erosion
    • 5.4.8. Pricing of Pipeline Agents
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. About the Authors
    • 5.6.1. Analyst
    • 5.6.2. Therapy Area Director
    • 5.6.3. Epidemiologist
    • 5.6.4. Global Head of Healthcare
    • 5.6.5. Global Director of Therapy Analysis and Epidemiology
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: 8MM Sales Forecast ($m) for PAD, 2014-2024
  • Table 2: 8MM, PAD Market - Drivers and Barriers, 2015
  • Table 3: 8MM, Key Companies' Relevant Key Marketed and Pipeline Drugs in the PAD Market, 2015
  • Table 4: Bayer's PAD Portfolio Assessment, 2015
  • Table 5: Janssen's PAD Portfolio Assessment, 2015
  • Table 6: AstraZeneca's PAD Portfolio Assessment, 2015
  • Table 7: Merck's PAD Portfolio Assessment, 2015
  • Table 8: Sanofi's PAD Portfolio Assessment, 2015
  • Table 9: Pfizer's PAD Portfolio Assessment, 2015
  • Table 10: Bristol-Myers Squibb's PAD Portfolio Assessment, 2015
  • Table 11: Otsuka Pharmaceutical's PAD Portfolio Assessment, 2015
  • Table 12: Abbreviations
  • Table 13: Key Launch Dates
  • Table 14: Key Patent Expiries
  • Table 15: High-Prescribing Physicians Non-KOLs Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for PAD by Region, 2014 and 2024
  • Figure 2: 8MM, Global PAD Sales by Drug Class, 2014 and 2024
  • Figure 3: Company Portfolio Gap Analysis in PAD, 2014-2024
Back to Top